Back to top
more

Illumina (ILMN)

(Real Time Quote from BATS)

$152.93 USD

152.93
1,714,060

+3.17 (2.12%)

Updated Nov 4, 2024 09:34 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is a Beat in Store for Zoetis (ZTS) This Earnings Season?

by Zacks Equity Research

Zoetis (ZTS) will report earnings and revenues, and provide pipeline updates when it releases second-quarter 2021 results.

Editas (EDIT) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On Editas' (EDIT) second-quarter earnings call, investor focus will likely be on the company's progress with the development of EDIT-101, its lead pipeline candidate.

Canopy Growth (CGC) to Report in Q1 Earnings: What's in Store?

by Zacks Equity Research

Continued robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal first quarter.

Is a Beat in the Cards for CVS Health (CVS) in Q2 Earnings?

by Zacks Equity Research

CVS Health's (CVS) consumer-centric digital approach to administer vaccines across the nation is expected to have strongly contributed to its Q2 performance within retail segment.

Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Abiomed (ABMD) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q1 sales.

Sorrento (SRNE) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Sorrento (SRNE) will provide updates on earnings and revenues when it releases second-quarter 2021 results.

What's in Store for Henry Schein (HSIC) in Q2 Earnings?

by Zacks Equity Research

Henry Schein's (HSIC) PPE sales from medical business are likely to have maintained momentum in Q2. Also, global recovery trends of its dental business are expected to reflect on Q2 results.

Vertex (VRTX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On Vertex's (VRTX) second-quarter earnings call, investor focus is likely to be on the sales performance of its triple combo CF drug Trikafta and pipeline progress.

How Investors Can Grab Better Returns for Medical Using the Zacks ESP Screener

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

CRISPR (CRSP) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On CRISPR Therapeutics' (CRSP) Q2 earnings call, investors will look forward to the company's advancement with its lead gene-editing candidate CTX001.

    What's in the Cards for Universal Health's (UHS) Q2 Earnings?

    by Zacks Equity Research

    Universal Health's (UHS) second-quarter results are likely to reflect improving revenues stemming from growing patient admissions, partly offset by high costs.

    Ecolab (ECL) to Report Q2 Earnings: What's in the Offing?

    by Zacks Equity Research

    Ecolab's (ECL) second-quarter results are likely to reflect continued strength in the Global Healthcare and Life Sciences segment.

    3 Reasons Why Growth Investors Shouldn't Overlook Illumina (ILMN)

    by Zacks Equity Research

    Illumina (ILMN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

    Can Illumina (ILMN) Keep the Earnings Surprise Streak Alive?

    by Zacks Equity Research

    Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

    All You Need to Know About Illumina (ILMN) Rating Upgrade to Buy

    by Zacks Equity Research

    Illumina (ILMN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?

    by Zacks Equity Research

    Is (ILMN) Outperforming Other Medical Stocks This Year?

    Illumina's (ILMN) NovaSeq Adoption Aids, Margin Woe Stays

    by Zacks Equity Research

    Illumina (ILMN) derives benefits from the cascading effect of the ACOG guidance on increasing coverage of NIPT for all pregnancies.

    Stock Market News for Jun 11, 2021

    by Zacks Equity Research

    Benchmarks closed in the green as investors shrugged off inflation report in agreement with the Fed's argument that jump in prices is temporary as demand exceed supply on account of the economy's recovery from the pandemic

    The Zacks Analyst Blog Highlights: Intel, NextEra Energy, PetroChina, Illumina and Biogen

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Intel, NextEra Energy, PetroChina, Illumina and Biogen

    Sheraz Mian headshot

    Top Research Reports for Intel, NextEra Energy & PetroChina

    by Sheraz Mian

    Today's Research Daily features new research reports on 16 major stocks, including Intel (INTC), NextEra Energy (NEE), and PetroChina Company (PTR).

    LHC Group (LHCG) Expands Hospice Presence with New Buyout

    by Zacks Equity Research

    LHC Group (LHCG) agrees to purchase Heart of Hospice to extend its hospice footprint in five states.

      Here's Why You Should Retain Allscripts (MDRX) Stock for Now

      by Zacks Equity Research

      Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and solid prospects of the Sunrise EHR platform.

      Here's Why You Should Retain PRA Health (PRAH) Stock for Now

      by Zacks Equity Research

      Investors continue to be optimistic about PRA Health (PRAH) owing to its strategic alliances and solid CRO market prospects.

      Baxter's (BAX) PrisMax 2 to Simplify Organ Support Therapies

      by Zacks Equity Research

      Baxter's (BAX) PrisMax 2 aims to enhance user experience and help in addressing the unique demands of the ICU.